In a patient with ulcerative colitis and iron deficiency anemia, what ferritin target should be aimed for and how should iron replacement be managed?

Ferritin Target and Iron Replacement Management in UC with Iron Deficiency Anemia

In UC patients with iron deficiency anemia, target a ferritin >100 μg/L (or >30 μg/L if no inflammation) and use intravenous iron as first-line therapy for active disease, severe anemia (Hb <100 g/L), or oral iron intolerance. 1, 2

Ferritin Targets Based on Inflammatory Status

The ferritin target depends critically on whether inflammation is present:

Without Active Inflammation:

• Target ferritin >30 μg/L 1, 2
• Iron deficiency is diagnosed when ferritin <30 μg/L
• Transferrin saturation <16-20% supports the diagnosis 3

With Active Inflammation (elevated CRP, clinical disease activity):

• Target ferritin >100 μg/L 1, 3, 2
• Ferritin up to 100 μg/L may still indicate iron deficiency due to ferritin being an acute phase reactant
• If ferritin is 30-100 μg/L with inflammation, assume combined iron deficiency and anemia of chronic disease 1, 3

When Using Erythropoiesis-Stimulating Agents:

• Target ferritin 200-500 μg/L 3
• Target transferrin saturation 30-40% 3
• This higher target ensures adequate iron availability for increased erythropoiesis

Iron Replacement Strategy

First-Line Therapy Selection

Use Intravenous Iron First-Line When: 3, 2

• Active UC (clinically or biochemically evident inflammation)
• Hemoglobin <100 g/L (severe anemia)
• Previous intolerance to oral iron
• Inadequate response to oral iron after 2 weeks
• Requiring erythropoiesis-stimulating agents

Consider Oral Iron Only When: 3, 2

• Disease is in remission (no clinical/biochemical inflammation)
• Mild anemia (Hb >100 g/L)
• Patient preference after counseling

Oral Iron Dosing (When Appropriate)

If oral iron is used in quiescent disease:

• Maximum 100 mg elemental iron daily 4, 5
• Consider alternate-day dosing to improve tolerability 6
• One ferrous sulfate 200 mg tablet daily (65 mg elemental iron) is reasonable 6
• Monitor response at 2 weeks—failure to increase Hb by ≥10 g/L predicts treatment failure 6

Critical Caveat: Oral iron should NOT be used in active disease because systemic inflammation (via hepcidin) blocks intestinal iron absorption, making oral therapy ineffective and potentially harmful through oxidative stress in the inflamed gut 3, 4.

Intravenous Iron Administration

Dose Calculation: Use the Ganzoni formula or simplified dosing table 1:

• Hb 10-12 g/dL (women) or 10-13 g/dL (men): 1000 mg if <70 kg, 1500 mg if ≥70 kg
• Hb 7-10 g/dL: 1500 mg if <70 kg, 2000 mg if ≥70 kg

Preparation Selection:

• Ferric carboxymaltose (FCM) or iron isomaltoside are commonly used 7, 8
• Important: FCM carries a 28.5% risk of hypophosphatemia; iron isomaltoside may be preferable 7
• Iron sucrose is safe in younger patients (<14 years) 8

Expected Response:

• Reticulocytosis occurs at 3-5 days 9
• Hemoglobin should rise ≥2 g/dL within 4 weeks 7
• Full response typically within 8-12 weeks 3

Monitoring Protocol

During Active Treatment:

• Check Hb, ferritin, transferrin saturation, and CRP at 2-4 weeks 3, 7
• If no response, reassess for ongoing blood loss, malabsorption, or other causes (B12/folate deficiency, bone marrow suppression) 3

Long-Term Surveillance:

• UC in remission: every 12 months 3
• Mild disease activity: every 6 months 3
• Active disease: every 3 months 2
• Recurrence rate exceeds 50% at 1 year, often indicating subclinical inflammation 3

Treatment Algorithm Summary

1. Assess inflammatory status (CRP, clinical activity scores)
2. Diagnose iron deficiency:
   • No inflammation: ferritin <30 μg/L
   • With inflammation: ferritin <100 μg/L or transferrin saturation <20%
3. Choose route:
   • Active disease/severe anemia/intolerance → IV iron
   • Quiescent disease + mild anemia → oral iron (max 100 mg/day)
4. Target ferritin:
   • No inflammation: >30 μg/L
   • With inflammation: >100 μg/L
   • With ESA therapy: 200-500 μg/L
5. Monitor response at 2-4 weeks
6. Switch to IV iron if oral fails

Additional Considerations

Treat the underlying UC first—controlling inflammation is essential for successful anemia management 3. However, this alone rarely normalizes hemoglobin, so iron supplementation remains necessary 3.

Avoid blood transfusion except for hemodynamic instability or severe symptomatic anemia unresponsive to other measures 3. Transfusion carries long-term risks and doesn't replenish iron stores 6.

Check B12 and folate at least annually, especially if macrocytosis is present 3.